These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 10439182)
1. Normal thymic uptake of 2-deoxy-2[F-18]fluoro-D-glucose. Alibazoglu H; Alibazoglu B; Hollinger EF; Ingram SA; Willoughby WA; LaMonica G; Ali A Clin Nucl Med; 1999 Aug; 24(8):597-600. PubMed ID: 10439182 [TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617 [TBL] [Abstract][Full Text] [Related]
3. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Giammarile F; Hafdi Z; Bournaud C; Janier M; Houzard C; Desuzinges C; Itti R; Sassolas G; Borson-Chazot F Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343 [TBL] [Abstract][Full Text] [Related]
4. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516 [TBL] [Abstract][Full Text] [Related]
5. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Lind P; Kohlfürst S Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610 [TBL] [Abstract][Full Text] [Related]
6. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330 [TBL] [Abstract][Full Text] [Related]
7. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387 [TBL] [Abstract][Full Text] [Related]
8. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792 [TBL] [Abstract][Full Text] [Related]
9. Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma. Godart V; Weynand B; Coche E; De Nayer P; Daumerie C J Endocrinol Invest; 2005 Dec; 28(11):1024-8. PubMed ID: 16483183 [TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871 [TBL] [Abstract][Full Text] [Related]
11. Thymic uptake after high-dose I-131 treatment in patients with differentiated thyroid carcinoma: a brief review of possible causes and management. Arce MB; Molina TC; Hernández TM; de la Cinta Calvo Morón M; Herrero CH; De La Riva Pérez PA; Montaño JC Endocrinol Nutr; 2015 Jan; 62(1):19-23. PubMed ID: 25160708 [TBL] [Abstract][Full Text] [Related]
12. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Boerner AR; Petrich T; Weckesser E; Fricke H; Hofmann M; Otto D; Weckesser M; Langen KJ; Knapp WH Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):231-6. PubMed ID: 11926385 [TBL] [Abstract][Full Text] [Related]